Arrowhead Pharmaceuticals, Inc.
General ticker "ARWR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B (TTM average)
Arrowhead Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 55.4%.
Estimated limits based on current volatility of 4.9%: low 60.25$, high 66.40$
Factors to consider:
- Total employees count: 609 (+16.0%) as of 2024
- Top business risk factors: Drug development risks, Geopolitical risks, Regulatory and compliance, Liquidity and credit risks, Cybersecurity threats
- Current price 148.8% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [12.00$, 29.51$]
- 2025-09-30 to 2026-09-30 estimated range: [10.40$, 25.99$]
Financial Metrics affecting the ARWR estimates:
- Negative: with PPE of -4.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.23 <= 0.33
- Negative: Shareholder equity ratio, % of 16.27 <= 18.93
- Positive: Inventory ratio change, % of 0.36 <= 0.84
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
Short-term ARWR quotes
Long-term ARWR plot with estimates
Financial data
| YTD | 2022-09-30 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating Revenue | $243.23MM | $240.74MM | $3.55MM |
| Operating Expenses | $421.74MM | $445.74MM | $604.63MM |
| Operating Income | $-178.51MM | $-205.00MM | $-601.08MM |
| Non-Operating Income | $5.80MM | $-1.49MM | $-11.38MM |
| Interest Expense | $0.00MM | $18.33MM | $32.35MM |
| R&D Expense | $297.31MM | $353.19MM | $505.87MM |
| Income(Loss) | $-172.71MM | $-206.49MM | $-612.46MM |
| Taxes | $3.79MM | $2.78MM | $-2.77MM |
| Profit(Loss)* | $-176.06MM | $-205.28MM | $-599.49MM |
| Stockholders Equity | $398.52MM | $271.34MM | $185.44MM |
| Inventory | $21.61MM | $0.00MM | $0.00MM |
| Assets | $691.94MM | $765.55MM | $1,139.80MM |
| Operating Cash Flow | $-136.13MM | $-153.89MM | $-462.85MM |
| Capital expenditure | $52.78MM | $176.74MM | $141.47MM |
| Investing Cash Flow | $-5.42MM | $-96.16MM | $-420.07MM |
| Financing Cash Flow | $65.19MM | $253.05MM | $870.52MM |
| Earnings Per Share** | $-1.67 | $-1.91 | $-5.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.